Serological response to pneumococcal vaccination in HAART-treated HIV-infected patients: one year follow-up study.
The aim of this study was to evaluate specific IgG responses against pneumococcal serotypes 1, 6B, 14, 19F, 23F at baseline, 1 and 12 months after vaccination with the 23-valent polysaccharide pneumococcal vaccine in 89 HAART-treated HIV-infected patients, 24 antiretroviral "naïve" HIV-infected and 30 non-HIV-infected healthy subjects. Levels of specific antipneumococcal IgG and the mean fold increase in IgG levels at 1 month as well as the kinetics of antibodies along the 12 months in all groups of HIV-infected patients and healthy subjects were similar. Neither CD4 cell count at baseline nor "nadir" CD4 cells correlated with the response to the vaccine. In conclusion, the immunogenicity conferred by the polysaccharide vaccine in HIV-infected patients under HAART is at least as good as that observed in healthy subjects.
Falcó
Vicenç
V
Infectious Disease Department, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Spain. vfalco@vhebron.net
Jordano
Queralt
Q
Cruz
María Jesús
MJ
Len
Oscar
O
Ribera
Esteve
E
Campins
Magda
M
Crespo
Manel
M
Ocaña
Inma
I
Rodrigo
María José
MJ
Pahissa
Albert
A
D017088:AIDS-Related Opportunistic Infections / Q000276:immunology / Q000517:prevention & control; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D005500:Follow-Up Studies; D015483:HIV Antibodies; D015658:HIV Infections / Q000150:complications / Q000276:immunology* / Q000382:microbiology; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D011008:Pneumococcal Infections / Q000276:immunology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000008:administration & dosage* / Q000276:immunology; D011134:Polysaccharides / Q000276:immunology; D016896:Treatment Outcome
D015483:HIV Antibodies; D007074:Immunoglobulin G; D022242:Pneumococcal Vaccines; D011134:Polysaccharides